{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:40Z","timestamp":1782337240637,"version":"3.54.5"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","award":["283\/37\/12.01.2026"],"award-info":[{"award-number":["283\/37\/12.01.2026"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008769","name":"Abt Global","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105267","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:24:21Z","timestamp":1773246261000},"page":"105267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Integrating venetoclax-based targeted and\/or immune therapies for chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"222","author":[{"given":"David","family":"Kegyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Muresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Bogdan","family":"Tigu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Borlea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horia","family":"Bumbea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda","family":"Buruiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105267_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine learning can identify newly diagnosed patients with CLL at high risk of infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10428194.2021.1973672","article-title":"Artificial intelligence models in chronic lymphocytic leukemia \u2013 recommendations toward state-of-the-art","volume":"63","author":"Agius","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib3","article-title":"A phase 2 study of zanubrutinib and venetoclax (ZV) in Relapsed or Refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"144","author":"Ahn","year":"2024","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib4","article-title":"Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +\/- Ibrutinib: Results of the Improve Study","volume":"142","author":"Albi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105267_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025028899","article-title":"The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL","author":"Al-Sawaf","year":"2025","journal-title":"Blood J."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105267_bib6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105267_bib7","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105267_bib8","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105267_bib9","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am. J. Cancer Res."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib10","article-title":"Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia","volume":"144","author":"Brieghel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105267_bib11","article-title":"Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia","author":"Brown","year":"2025","journal-title":"Blood J. Blood. 2024027009."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105267_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib13","article-title":"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105267_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105267_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat. Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105267_bib16","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood.2024026879","article-title":"Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: The SAKK 34\/17 trial","volume":"145","author":"Condoluci","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105267_bib17","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1016\/S2352-3026(22)00211-3","article-title":"Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): A multicentre, open-label, phase 2 trial","volume":"9","author":"Cramer","year":"2022","journal-title":"Lancet Haematol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib18","article-title":"SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL","volume":"41","author":"Crombie","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib19","article-title":"A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL) or Richter\u2019s Syndrome (RS)","volume":"144","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.critrevonc.2026.105267_bib20","first-page":"P682","article-title":"Retreatment With Venetoclax And Rituximab Combination Following Disease Progression While Off Therapy In Patients With Chronic Lymphocytic Leukemia","volume":"8","author":"Brander","year":"2024","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105267_bib21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/bloodadvances.2024014633","article-title":"A phase 1 study of the CDK9 inhibitor voruciclib in relapsed\/refractory acute myeloid leukemia and B-cell malignancies","volume":"9","author":"Davids","year":"2025","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105267_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100885","article-title":"Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b\/2 study","volume":"6","author":"Davids","year":"2025","journal-title":"Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105267_bib23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: A single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105267_bib24","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Na\u00efve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease","volume":"43","author":"Davids","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105267_bib25","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell malignancies: A comprehensive review","volume":"18","author":"Davies","year":"2022","journal-title":"Future Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib26","volume":"138","author":"Eichhorst","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105267_bib27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib28","article-title":"Quality of Life in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax","volume":"144","author":"Eurelings","year":"2024","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib29","article-title":"BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"41","author":"Eyre","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105267_bib30","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105267_bib31","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.287799","article-title":"Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: Non-traditional factors may play a role in clinical practice","author":"Frustaci","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105267_bib32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105267_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105267_bib34","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood.2024026685","article-title":"MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: Primary end point analysis from the CLL2-BZAG trial","volume":"145","author":"F\u00fcrstenau","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib35","article-title":"Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA\/CLL13 Trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib36","article-title":"Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study","volume":"43","author":"Ghia","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105267_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.27563","article-title":"Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study","volume":"100","author":"Ghosh","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105267_bib38","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib39","article-title":"Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"142","author":"Hampel","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105267_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jha2.177","article-title":"Addition of rituximab in relapsed\/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy","volume":"2","author":"Handunnetti","year":"2021","journal-title":"eJHaem"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/bloodadvances.2023010693","article-title":"Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed\/refractory chronic lymphocytic leukemia","volume":"8","author":"Hill","year":"2024","journal-title":"Blood Adv."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-136960","article-title":"Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed\/Refractory CLL in the Blood Cancer UK TAP Clarity Trial","volume":"136","author":"Hillmen","year":"2020","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105267_bib44","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib45","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3390\/curroncol30020148","article-title":"Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia","volume":"30","author":"Hoffmann","year":"2023","journal-title":"Curr. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib46","article-title":"Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL\/SLL - the Avenue-2 Trial","volume":"144","author":"Huang","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105267_bib47","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood.V99.7.2285","article-title":"The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile","volume":"99","author":"Huang","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105267_bib48","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: Obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/ TP53 mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105267_bib49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: Lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib50","article-title":"Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"144","author":"Jain","year":"2024","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib51","article-title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib52","article-title":"Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data","volume":"142","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105267_bib53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib54","article-title":"MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)","volume":"144","author":"Jamroziak","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105267_bib55","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: Final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105267_bib56","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): Primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105267_bib57","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105267_bib58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105267_bib59","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105267_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41420-025-02678-4","article-title":"Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and\/or immune therapies","volume":"11","author":"Kegyes","year":"2025","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105267_bib61","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): Primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib62","article-title":"Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL","volume":"144","author":"Kittai","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105267_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105267_bib64","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib65","article-title":"Phase I Study of Response-Adapted Treatment with Venetoclax, Obinutuzumab, and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-Cell Malignancies","volume":"142","author":"Lakhotia","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib66","article-title":"Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Following at Least One Prior Therapy","volume":"142","author":"Lavie","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105267_bib67","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/10428194.2024.2310144","article-title":"Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"65","author":"Lei","year":"2024","journal-title":"Leuk. & Lymphoma"},{"issue":"S1","key":"10.1016\/j.critrevonc.2026.105267_bib68","first-page":"PS1568","article-title":"Using Minimal Residual Disease Status to Guide Venetoclax Treatment duration in Patients with CLL: interim result from the phase II VENETOSTOP study","volume":"9","author":"Leora Boussi","year":"2025","journal-title":"HemaSphere"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib69","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2022-163209","article-title":"Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL\/Sll; First Interim Analysis of the Phase 2 HOVON 158\/Next STEP Trial","volume":"140","author":"Levin","year":"2022","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib70","article-title":"Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158\/Next STEP Phase 2 Trial","volume":"144","author":"Levin","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105267_bib71","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/bloodadvances.2023011327","article-title":"Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon","volume":"8","author":"Lew","year":"2024","journal-title":"Blood Adv."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib72","article-title":"Phase 1\/2 studies of DZD8586 in CLL\/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105267_bib73","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation\u2013induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105267_bib74","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06136-6","article-title":"Comparative safety of different first-line treatments for chronic lymphocytic leukemia\/small lymphocytic lymphoma: A systematic review and network meta-analysis","author":"Liu","year":"2024","journal-title":"Ann. Hematol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105267_bib75","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/blood.2024024341","article-title":"Venetoclax dose escalation rapidly activates a BAFF\/BCL-2 survival axis in chronic lymphocytic leukemia","volume":"144","author":"Luo","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105267_bib76","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105267_bib77","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3324\/haematol.2022.282116","volume":"108","author":"Mauro","year":"2023","journal-title":"Haematologica"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib78","article-title":"Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk: Final Results of the Eradic Trial from the Filo Group","volume":"144","author":"Michallet","year":"2024","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib79","article-title":"First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study","volume":"142","author":"Moreno","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105267_bib80","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib81","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2022-166700","article-title":"MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study","volume":"140","author":"Munir","year":"2022","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib82","article-title":"Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC)","volume":"43","author":"Munir","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105267_bib83","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/bloodadvances.2024015180","article-title":"Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: Phase 2 VISION\/HO141 trial","volume":"9","author":"Niemann","year":"2025","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105267_bib84","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib85","article-title":"First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis","volume":"144","author":"Niemann","year":"2024","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib86","article-title":"BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"42","author":"Ozcan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"S1","key":"10.1016\/j.critrevonc.2026.105267_bib87","first-page":"PB2666","article-title":"Venetoclax-Rituximab Fixed Duration Combination in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukaemia (CLL) including Those after BTK-Inhibitors in A Real-World Setting","volume":"9","author":"Panayiotidis","year":"2025","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib88","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.leu.2401302","article-title":"Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy","volume":"13","author":"Puthier","year":"1999","journal-title":"Leukemia"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib89","article-title":"Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL","volume":"144","author":"Reville","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105267_bib90","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: The phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib91","volume":"142","author":"Roeker","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib92","article-title":"Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105267_bib93","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1470-2045(24)00260-2","article-title":"GAIA\/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia","volume":"25","author":"Rogers","year":"2024","journal-title":"Lancet Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib94","article-title":"Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL","volume":"40","author":"Rogers","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105267_bib95","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Na\u00efve and Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib96","article-title":"Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL","volume":"142","author":"Rogers","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib97","doi-asserted-by":"crossref","first-page":"9871","DOI":"10.1182\/blood-2022-169986","article-title":"Updated Results from a Phase I\/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL) or Richter\u2019s Syndrome (RS)","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105267_bib98","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","article-title":"MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol."},{"issue":"S3","key":"10.1016\/j.critrevonc.2026.105267_bib99","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000974572.50349.42","article-title":"PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS \u2013 DATA FROM THE OBSERVATIONAL STUDY VERVE","volume":"7","author":"Schwaner","year":"2023","journal-title":"HemaSphere"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105267_bib100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105267_bib101","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib102","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105267_bib103","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and Venetoclax for Patients With Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma With and Without Del(17p)\/ TP53 Mutation: SEQUOIA Arm D Results","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib104","article-title":"A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL)","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib105","article-title":"CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations","volume":"144","author":"Sharman","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105267_bib106","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1080\/10428194.2020.1811271","article-title":"Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: A network meta-analysis","volume":"61","author":"Sheng","year":"2020","journal-title":"Leuk. & Lymphoma"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib107","article-title":"Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed\/Refractory (rel\/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study","volume":"138","author":"Siddiqi","year":"2021","journal-title":"Blood"},{"issue":"10402","key":"10.1016\/j.critrevonc.2026.105267_bib108","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): A multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib109","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105267_bib110","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105267_bib111","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3026(19)30085-7","article-title":"Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: A retrospective, pooled cohort study with external validations","volume":"6","author":"Soumerai","year":"2019","journal-title":"Lancet Haematol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105267_bib112","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1080\/10428194.2021.1964020","article-title":"Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor","volume":"62","author":"Staber","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105267_bib113","volume":"39","author":"Stephens","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105267_bib114","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2020.261107","article-title":"Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)","volume":"106","author":"Stilgenbauer","year":"2020","journal-title":"Haematologica"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib115","article-title":"Early obinutuzumab significantly increases bone marrow undetectable MRD (10-4 sensitivity) (uMRD4) rate when combined with acalabrutinib and venetoclax in a randomized phase II trial for treatment na\u00efve CLL","volume":"144","author":"Swaminathan","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105267_bib116","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105267_bib117","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.2024026672","article-title":"Novel mechanisms of resistance in CLL: Variant BTK mutations in second-generation and noncovalent BTK inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib118","article-title":"Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial","volume":"138","author":"Tedeschi","year":"2021","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib119","article-title":"Real-world venetoclax-obinutuzumab in 232 treatment naive CLL patients: feasibility and tolerability","volume":"142","author":"Tedeschi","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib120","article-title":"Improved innate immune function upon preemptive short-term acalabrutinib and venetoclax in Newly Diagnosed CLl patients with high risk of infections: translational findings from the prevent-acall clinical trial","volume":"144","author":"Teglgaard","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105267_bib121","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41375-023-01901-4","article-title":"Venetoclax consolidation in high-risk CLL treated with ibrutinib for \u22651 year achieves a high rate of undetectable MRD","volume":"37","author":"Thompson","year":"2023","journal-title":"Leukemia"},{"issue":"ement_1","key":"10.1016\/j.critrevonc.2026.105267_bib122","article-title":"Veneto-STOp study: sequential assessment of minimal residual disease By Next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients","volume":"134","author":"Ujjani","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105267_bib123","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.2023020195","article-title":"Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL","volume":"142","author":"Van Der Straten","year":"2023","journal-title":"Blood"},{"issue":"6189","key":"10.1016\/j.critrevonc.2026.105267_bib124","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105267_bib125","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/cancers16071290","article-title":"Innovative COmbinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review","volume":"16","author":"Visentin","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105267_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27009","article-title":"Continuous venetoclax in treatment-naive TP 53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study","volume":"98","author":"Visentin","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105267_bib127","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105267_bib128","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"ement_1","key":"10.1016\/j.critrevonc.2026.105267_bib129","article-title":"A Phase I Study Combining CDK2\/9 Inhibitor CYC065 with Venetoclax, a BCL2 inhibitor, to treat relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"134","author":"Wierda","year":"2019","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136317","article-title":"Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Na\u00efve or Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"136","author":"Woyach","year":"2020","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105267_bib131","article-title":"A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\u2265 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105267_bib132","article-title":"Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)","volume":"41","author":"Woyach","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105267_bib133","first-page":"1","article-title":"Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL \u2013 real-life data analysis of the Polish Adult leukemia group","author":"Zielonka","year":"2025","journal-title":"Leuk. & Lymphoma"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:43:31Z","timestamp":1778481811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":133,"alternative-id":["S104084282600154X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105267","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating venetoclax-based targeted and\/or immune therapies for chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105267"}}